Linked Life Data

21226820

Source:http://linkedlifedata.com/resource/pubmed/id/21226820

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-2-23
pubmed:abstractText
Recent studies indicate that type 2 diabetes is associated with an increased secretion of both hepatic and intestinal lipoproteins, leading to the accumulation of atherogenic triglyceride (TG)-rich lipoproteins. Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 that has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes presumably through incretin hormone-mediated improvements in islet function. The objective of the present study is to examine the effects of treatment with sitagliptin on postprandial lipid and incretin hormone levels as well as glucose homeostasis in patients with type 2 diabetes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1463-1326
pubmed:author
pubmed:copyrightInfo
© 2011 Blackwell Publishing Ltd.
pubmed:issnType
Electronic
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
366-73
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
pubmed:affiliation
Department of Food Sciences, Institute of Nutraceuticals and Functional Foods, Laval University, Quebec City, Québec, Canada.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't